COVID-19 Vaccine Standards Questioned at FDA Advisory Meeting COVID-19 Vaccine Standards Questioned at FDA Advisory Meeting

FDA advisers on Thursday heard calls for changes in how the agency plans to review applications for clearance of COVID-19 vaccines.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news

Related Links:

Saudi Med J. 2021 Dec;42(12):1341-1352. doi: 10.15537/smj.2021.42.12.20210576.ABSTRACTOBJECTIVES: To identify the self-reported vaccine-related side effects among healthcare professionals (HCPs) in the Jazan province, Saudi Arabia, and determine the associated socio-demographic factors. With the recent second and third waves of coronavirus disease -19 (COVID-19) infections worldwide, the race is not only to encourage but also to achieve mass vaccination.METHODS: A total of 397 HCPs from across Jazan province participated in an anonymous online cross-sectional survey conducted for a period of 45 days (March 30, 2021 to May ...
Source: Saudi Medical Journal - Category: Middle East Health Authors: Source Type: research
Acta Med Port. 2021 Jun 30;34(7-8):541-547. doi: 10.20344/amp.16096. Epub 2021 May 21.ABSTRACTThe first reports of hypersensitivity reactions following the rollout of COVID-19 vaccination programs have raised public concern. Given the recent availability and novel mechanisms of COVID-19 vaccines, there is limited data on possible hypersensitivity reactions. Although it seems rare, the incidence of anaphylaxis for approved COVID-19 vaccines has been suggested as being higher when compared to previous vaccines. Adequate risk assessment, recognition, classification, and management of hypersensitivity reactions is crucial to e...
Source: Acta Medica Portuguesa - Category: General Medicine Authors: Source Type: research
Vaccine-related severe allergic reactions are of growing public concern given reports of anaphylaxis after COVID-19 mRNA vaccination1 and may contribute to vaccine hesitancy and incomplete vaccination.2 Little is known about prior trends in healthcare utilization for vaccine-related severe allergic reactions among the United States (US) adult population.3 Understanding these trends over time, especially prior to the COVID-19 pandemic, may be helpful to contextualize COVID-19 vaccine-related allergic reactions and inform public understanding of the overall risk of vaccine-related severe allergic reactions.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Acta Biomed. 2021 Nov 29;92(S7):e2021519. doi: 10.23750/abm.v92iS7.12384.ABSTRACTHypersensitivity reactions to polyethylene glycol (PEG) is an emerging challenge and the interest about this disease is growing since PEG is considered one of the possible causes of coronavirus disease 2019 (COVID 19) vaccine-associated anaphylaxis. PEG is used in a wide variety of pharmaceutical, medical, industrial, cosmetic, and food products and can be an active ingredient or used as an excipient. PEG is present in several medications, and it may or may not be present in different formulations and dosages of the same drug. Lack of standard...
Source: Acta Bio-Medica : Atenei Parmensis - Category: General Medicine Authors: Source Type: research
A new variant of SARS-CoV-2 first reported in South Africa is raising alarms for health officials around the world, leading to fresh travel restrictions amid fears it could be resistant to existing vaccines. Researchers in South Africa conducting genetic analysis of COVID-19 virus cases determined that a new variant, B.1.1.529, had been found in cases in South Africa, Botswana, and a traveler who had traveled from South Africa to Hong Kong, the country’s health minister announced on Nov. 25. The following day, Belgian health officials reported the first case of the new variant discovered in Europe. That same day, the...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
Ann Allergy Asthma Immunol. 2021 Dec;127(6):703. doi: 10.1016/j.anai.2021.09.007.NO ABSTRACTPMID:34823756 | PMC:PMC8608549 | DOI:10.1016/j.anai.2021.09.007
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
ConclusionCollectively, our findings indicated that the MQ-VET is a valid and reliable tool that will help to standardize future evaluations of online medical videos.
Source: Irish Journal of Medical Science - Category: General Medicine Source Type: research
Ann Allergy Asthma Immunol. 2021 Nov 20:S1081-1206(21)01274-6. doi: 10.1016/j.anai.2021.11.014. Online ahead of print.NO ABSTRACTPMID:34813953 | PMC:PMC8605811 | DOI:10.1016/j.anai.2021.11.014
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
We understand the concerns expressed by Drs Mungmunpuntipantip and Wiwanitkit regarding the efficacy and safety of messenger (m)RNA vaccines in patients with common variable immunodeficiency (CVID); however, we still strongly stick to the conclusions expressed in our report.1 With regard to efficacy, the aim of our study was to evaluate whether patients with CVID could generate neutralizing antibodies against severe acute respiratory syndrome coronavirus 2, and all but 1 actually did.1 Clearly, as already mentioned in the article, evaluation of the clinical significance of these antibodies (ie, protection against severe ma...
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Commentary Source Type: research
We would like to share our ideas on the article entitled “Detection of neutralizing anti–severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines.”1 Romano et al1 concluded that “CVID patients must be included in COVID-19 vaccination programs becaus e of the ability of mRNA vaccines to safely induce production of neutralizing antibodies in this category of patients.” Given that Romano et al1 noted that the production of neutralizing antibodies did not mean protection, it is, therefore, ...
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Correspondence Source Type: research
More News: Allergy | Allergy & Immunology | COVID-19 | Infectious Diseases | Vaccines